Innovation & intellectual property · 04/03/1999Updated: 10/17/2026 · 1 min read
Vivus Pharmaceuticals Granted Interim Extension for U.S. Patent 4229449
Summary
The U.S. Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,229,449, which covers the pharmaceutical compound roboxetine mesylate, used in the treatment of ADHD and depression.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →